---
document_datetime: 2025-11-12 13:29:24
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/kaftrio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: kaftrio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.4735535
conversion_datetime: 2025-12-26 09:45:17.954119
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Kaftrio

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number     | Scope                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|------------------------|---------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA_IN / | B.II.g.5 Implementation of changes foreseen | 17/10/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000306834                     | in an approved change management protocol - B.II.g.5.a The implementation of the change requires no further supportive data - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000290155 | C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - C.I.4.z Product Information update for a medicinal product containing more than one active substance, in order to include significant changes. Those changes were already assessed by a EU competent authority for a medicinal product containing one of the active substances, and the same wording will be used for the combination product. - Accepted Update of section 4.5 of the SmPC in order to include information regarding concomitant use with ciprofloxacin, based on results from the open-label, Phase 1 drug-drug interaction (DDI) study VX13-770-017, characterizing the impact of ciprofloxacin on ivacaftor (IVA) and tezacaftor (TEZ) exposures. In addition, the MAH took the opportunity to introduce minor editorial and formatting changes to the PI, and to remove the list of local representatives in the PL. | 16/10/2025 | SmPC, Labelling and PL | The following information regarding concomitant use with ciprofloxacin has been added in section 4.5 of the SmPC: ELX/TEZ/IVA was not evaluated for concomitant use with ciprofloxacin. However, ciprofloxacin had no clinically relevant effect on the exposure of TEZ or IVA and is not expected to have a clinically relevant effect on the exposure of ELX. Therefore, no dose adjustment is necessary during concomitant administration of IVA/TEZ/ELX with ciprofloxacin. For more information, please refer to the Summary of Product Characteristics. |
| Variation type II / EMA/VR/0000280845 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 04/09/2025 |                        | Submission of the 96-weeks of treatment report (Part A) for study VX20-445-112 (Study 112), listed                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                                          | specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted Submission of the 96-weeks of treatment report (Part A) for study VX20-445-112 (Study 112), listed as a category 3 study in the RMP; this is a Phase 3, open-label, extension study evaluating the long-term safety and efficacy of ELX/TEZ/IVA combination therapy in subjects with cystic fibrosis who are 2 years of age and older. The RMP version 10.1 has also been submitted.   |            |     | as a category 3 study in the RMP; this is a Phase 3, open-label, extension study evaluating the long- term safety and efficacy of ELX/TEZ/IVA combination therapy in subjects with cystic fibrosis who are 2 years of age and older. The RMP version 10.1 has also been submitted.   |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA_IN / EMA/VR/0000288205 | B.II.g.5 Implementation of changes foreseen in an approved change management protocol - B.II.g.5.a The implementation of the change requires no further supportive data - Accepted                                                                                                                                                                                                                                                                                                                                | 28/07/2025 | N/A |                                                                                                                                                                                                                                                                                      |
| Variation type IB / EMA/VR/0000268871    | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z - to provide an updated Environmental Risk Assessment (ERA) and its associated study reports to fulfill the commitment made during the initial marketing authorisation for Kaftrio (EMEA/H/C/005269/0000) and due by 30 April 2025.                                                                                                                                                                                          | 11/07/2025 | N/A |                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000273766    | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.a The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer - Accepted   | 16/06/2025   | N/A        |      |                                                                                                                                                                                                |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA_IN / EMA/VR/0000273627 | B.II.g.5 Implementation of changes foreseen in an approved change management protocol - B.II.g.5.a The implementation of the change requires no further supportive data - Accepted                                                                                                                                                                                                                                                                                       | 20/05/2025   | N/A        |      |                                                                                                                                                                                                |
| Variation type IB / EMA/VR/0000261391    | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.1 As packaged for sale (supported by real time data) - Accepted                                                                                                                                                                                                                                                                                                                              | 10/04/2025   | 17/07/2025 | SmPC | To extend the shelf-life of the finished product Kaftrio (ivacaftor/tezacaftor/elexacaftor) 37.5 mg/25 mg/50 mg film-coated tablets (EU/1/20/1468/002) as packaged for sale from 3 to 4 years. |